A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
City of Hope Medical Center
City of Hope Medical Center
Scripps Health